STOCK TITAN

Evogene (EVGN) director Leon Recanati buys 800,000 shares, lifts stake to 5.7%

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D

Rhea-AI Filing Summary

Evogene Ltd. investor and director Leon Recanati filed a Schedule 13D reporting beneficial ownership of 894,836 ordinary shares, or 5.7% of Evogene’s outstanding ordinary shares. This includes 883,886 shares held directly and 10,950 shares underlying options that are currently exercisable or exercisable within 60 days of August 4, 2026.

On August 4, 2026, he purchased 800,000 ordinary shares in open-market transactions at a weighted average price of $0.50 per share, for aggregate consideration of approximately $400,000, using personal funds. Recanati states he acquired the shares for investment purposes and, as a director, intends to vote all shares he beneficially owns in favor of the slate of director nominees put forward by Evogene’s current board at the 2026 annual general meeting, which includes a contested director election. He indicates he may buy or sell additional Evogene securities in the future depending on conditions.

Positive

  • None.

Negative

  • None.

Filing Explained

The filing confirms that Leon Recanati has sole voting and dispositive power over 894,836 ordinary shares, or 5.7% of Evogene, with no shared power or related securities agreements disclosed; this clarifies his stake’s voting mechanics before the September 4, 2026 contested annual meeting.

Beneficial ownership 894,836 ordinary shares Aggregate shares beneficially owned by Leon Recanati as of August 4, 2026
Ownership percentage 5.7% Portion of Evogene’s outstanding ordinary shares beneficially owned by Recanati
Shares outstanding 15,801,407 ordinary shares Evogene ordinary shares outstanding as of July 27, 2026, used for ownership calculation
Directly held shares 883,886 ordinary shares Ordinary shares of Evogene held directly by Recanati
Option-based shares 10,950 ordinary shares Shares underlying options currently exercisable or within 60 days of August 4, 2026
Recent purchase size 800,000 ordinary shares Shares bought on August 4, 2026 in open-market transactions
Weighted average purchase price $0.50 per share Price paid for the 800,000 ordinary shares purchased on August 4, 2026
Aggregate consideration approximately $400,000 Total amount paid for the 800,000 ordinary shares acquired on August 4, 2026
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13G to report the acquisition"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
beneficially owns financial
"the Reporting Person beneficially owns an aggregate of 894,836 Ordinary Shares"
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
sole dispositive power financial
"The Reporting Person has sole voting power and sole dispositive power with respect to all 894,836"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
ordinary shares financial
"Ordinary shares, par value NIS 0.20 per share"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
open market transactions financial
"representing the purchase of 800,000 Ordinary Shares in open market transactions on August 4, 2026"
Open market transactions are the buying and selling of a company’s shares or other securities conducted on public exchanges or through the wider market rather than through private deals or negotiated placements. They matter to investors because these trades change supply and demand in real time—like shoppers affecting a store’s inventory—and so can move prices, signal management or investor sentiment, affect liquidity, and alter ownership stakes that influence future returns and risk.
weighted average price financial
"at a weighted average price of $0.50 per share"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

How many Evogene (EVGN) shares does Leon Recanati report owning?

Leon Recanati reports beneficial ownership of 894,836 Evogene ordinary shares, representing approximately 5.7% of the company’s outstanding ordinary shares. This total includes 883,886 shares held directly and 10,950 shares underlying currently exercisable options.

What recent Evogene (EVGN) share purchase did Leon Recanati disclose?

On August 4, 2026, Leon Recanati purchased 800,000 Evogene ordinary shares in open-market transactions at a weighted average price of $0.50 per share. The aggregate consideration was approximately $400,000, funded from his personal resources.

What percentage of Evogene (EVGN) does 894,836 shares represent?

The 894,836 Evogene ordinary shares reported by Leon Recanati represent approximately 5.7% of Evogene’s outstanding ordinary shares. This percentage is based on 15,801,407 shares outstanding as of July 27, 2026, as reported by Evogene.

How does Leon Recanati plan to vote his Evogene (EVGN) shares at the 2026 AGM?

For Evogene’s 2026 annual general meeting, which includes a contested director election, Leon Recanati states he intends to vote all ordinary shares he beneficially owns in favor of the director nominees nominated by the current board of Evogene.

What is Leon Recanati’s role at Evogene (EVGN) and investment intent?

Leon Recanati serves as a member of Evogene’s board of directors and reports acquiring the ordinary shares for investment purposes. He indicates he may later acquire additional Evogene securities or dispose of some of his holdings, depending on various factors.

Does anyone share voting or dispositive power over Leon Recanati’s Evogene (EVGN) shares?

No. The filing states Leon Recanati has sole voting power and sole dispositive power over all 894,836 Evogene ordinary shares he beneficially owns, and that no other person shares voting or dispositive power over these securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





M4119S187

(CUSIP Number)
Nitsan Deutsch
13 Gad Feinstein Street, Park Rehovot,
Rehovot, IL, 7638517
972-8-9311900

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
08/04/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
(1) The percentage of Ordinary Shares beneficially owned by the Reporting Person is based on 15,801,407 Ordinary Shares outstanding as of July 27, 2026, as reported by the Issuer in the Issuer's Proxy Statement for its 2026 Annual General Meeting of Shareholders, dated July 31, 2026, attached as Exhibit 99.2 to the Issuer's Form 6-K that was furnished to the U.S. Securities and Exchange Commission on July 31, 2026. The aggregate beneficial ownership includes 10,950 Ordinary Shares underlying share options held by the Reporting Person that are currently exercisable or exercisable within 60 days of August 4, 2026.


SCHEDULE 13D


RECANATI LEON
Signature:/s/ Leon Recanati
Name/Title:Leon Recanati
Date:08/11/2026